Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

716 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
COVID-19-associated mucormycosis: A review of an emergent epidemic fungal infection in the era of COVID-19 pandemic.
Chamola V, Mohammadi R, Nair H, Goyal A, Patel A, Hassija V, Bassetti M, Narang P, Paredes R, Santos JR, Hashemi SJ, Sani MP, Shirani K, Alijani N, Naeini BA, Pourazizi M, Abtahi SH, Khorvash F, Khanjari M, Ahmadikia K. Chamola V, et al. Among authors: paredes r. J Res Med Sci. 2022 Jul 29;27:57. doi: 10.4103/jrms.jrms_1090_21. eCollection 2022. J Res Med Sci. 2022. PMID: 36092491 Free PMC article. Review.
HLA class I protective alleles in an HIV-1-infected subject homozygous for CCR5-Δ32/Δ32.
Ballana E, Riveira-Munoz E, Pou C, Bach V, Parera M, Noguera M, Santos JR, Badia R, Casadellà M, Clotet B, Paredes R, Martínez MA, Brander C, Esté JA. Ballana E, et al. Among authors: paredes r. Immunobiology. 2013 Apr;218(4):543-7. doi: 10.1016/j.imbio.2012.06.012. Epub 2012 Jun 28. Immunobiology. 2013. PMID: 22818666 Free article.
Improved prediction of salvage antiretroviral therapy outcomes using ultrasensitive HIV-1 drug resistance testing.
Pou C, Noguera-Julian M, Pérez-Álvarez S, García F, Delgado R, Dalmau D, Álvarez-Tejado M, Gonzalez D, Sayada C, Chueca N, Pulido F, Ibáñez L, Rodríguez C, Casadellà M, Santos JR, Ruiz L, Clotet B, Paredes R. Pou C, et al. Among authors: paredes r. Clin Infect Dis. 2014 Aug 15;59(4):578-88. doi: 10.1093/cid/ciu287. Epub 2014 May 29. Clin Infect Dis. 2014. PMID: 24879788 Clinical Trial.
Monotherapy with boosted PIs as an ART simplification strategy in clinical practice.
Santos JR, Llibre JM, Berrio-Galan D, Bravo I, Miranda C, Pérez-Alvarez S, Pérez-Alvarez N, Paredes R, Clotet B, Moltó J. Santos JR, et al. Among authors: paredes r. J Antimicrob Chemother. 2015 Apr;70(4):1124-9. doi: 10.1093/jac/dku509. Epub 2014 Dec 18. J Antimicrob Chemother. 2015. PMID: 25525196
The lipid-lowering effect of tenofovir/emtricitabine: a randomized, crossover, double-blind, placebo-controlled trial.
Santos JR, Saumoy M, Curran A, Bravo I, Llibre JM, Navarro J, Estany C, Podzamczer D, Ribera E, Negredo E, Clotet B, Paredes R; Tenofovir/emtricitabine inflUence on LIPid metabolism (TULIP) Study Group. Santos JR, et al. Among authors: paredes r. Clin Infect Dis. 2015 Aug 1;61(3):403-8. doi: 10.1093/cid/civ296. Epub 2015 Apr 13. Clin Infect Dis. 2015. PMID: 25870325 Clinical Trial.
716 results